Blood pressure pills may stop prehypertension from becoming Full-Blown disease
NCT ID NCT07652567
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether giving low-dose blood pressure medication to people with high-normal blood pressure and other risk factors could prevent them from developing full-blown hypertension, diabetes, or heart problems. 690 participants aged 50-79 were given either telmisartan, indapamide, or a placebo. The goal was to see if these drugs could reduce the risk of new-onset hypertension, diabetes, and cardiovascular events like stroke or heart attack.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Telmisartan and Indapamide
- What this could lead to
- If successful, this could show that low-dose blood pressure medication helps prevent the onset of hypertension and related heart issues in at-risk individuals.
- What could go wrong
- This is a completed study, but results may not apply to everyone. The drugs have side effects, and the benefit may be small for some people.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
690 people
The number who actually took part.
- Started
-
Jan 2007
- Finished
-
Apr 2026
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
50 to 79 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Age: 50-79 years, regardless of sex. 2. Blood Pressure: Systolic blood pressure (SBP) 130 ≤ SBP \< 140 mmHg and/or diastolic blood pressure (DBP) 85 ≤ DBP \< 90 mmHg. 3. Presence of at least one cardiovascular risk factor. 4. Capacity to provide informed consent. Exclusion Criteria: 1. Diabetes mellitus (FPG ≥ 7.0 mmol/L and/or OGTT 2h PG ≥ 11.1 mmol/L). 2. Hypertension (SBP ≥ 140 mmHg and/or DBP ≥ 90 mmHg) or current use of antihypertensive medication. 3. Participation in another clinical trial within 3 months prior to enrollment or concurrently with this study. 4. Significant renal impairment (serum creatinine ≥ 2.5 mg/dL). 5. Significant hepatic dysfunction (ALT \> 2 × upper limit of normal \[ULN\]). 6. Serum potassium \< 3.5 mmol/L or \> 5.6 mmol/L. 7. Known hypersensitivity to the investigational drugs used in this study. 8. History of stroke or myocardial infarction within 3 months prior to study entry. 9. Undergoing or scheduled for percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) within 3 months prior to study start. 10. Other serious medical conditions (e.g., malignant tumors). 11. Pregnant women or women of childbearing potential who are not using effective contraception or likely to become pregnant. 12. Patients who are bedridden or unable to attend clinic visits. 13. Any other condition requiring antihypertensive medication. 14. Any indication or contraindication for the investigational drug or other antihypertensive agents. 15. Subjects deemed unsuitable for inclusion by the investigator.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for High-normal blood pressure are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Qilu Hospital of Shandong University
Jinan, Shandong, 250000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.